吲哚布芬联合替格瑞洛对AMI患者PCI术后冠状动脉血流、心功能、炎症、血小板及出血的影响OA

Objective To investigate the effects of indobufen combined with ticagrelor on coronary blood flow,cardiac function,inflammation,platelets and bleeding in patients with acute myocardial infarction(AMI)after percutaneous coronary intervention(PCI).Methods A total of 208 patients with acute ST-segment ele-vation myocardial infarction,who admitted to the hospital and underwent PCI from December 2020 to Decem-ber 2022 were selected as the research subjects.According to the random number table method,the patients were divided into study group and control group,with 104 cases in each group.The control group was treated with aspirin combined with ticagrelor on the basis of conventional treatment,and the study group was treated with indobufen combined with ticagrelor on the basis of conventional treatment.Both groups were treated for 4 weeks.The coronary blood flow parameters[coronary flow velocity reserve(CFVR),peak diastolic flow ve-locity(DPV)and peak systolic flow velocity(SPV)of left anterior descending artery],cardiac function inde-xes[left ventricular end diastolic diameter(LVEDD)and left ventricular ejection fraction(LVEF)]and in-flammatory factors[serum interleukin-6(IL-6)]and tumor necrosis factor-α(TNF-α)]and platelet parame-ters[mean platelet volume(MPV)and platelet count(PLT)]were recorded before and after treatment.The occurrence of adverse reactions during treatment,as well as bleeding events during hospitalization and within 6 months after discharge,were recorded simultaneously.Results After treatment,LVEF,MPV,CFVR,DPV and SPV in the two groups were higher than those before treatment,and LVEF,MPV,CFVR,DPV and SPV in the study group were higher than those in the control group,with statistically significant differences(P<0.05);LVEDD in the two groups after treatment was less than that before treatment,PLT and TNF-α,IL-6 levels were lower than those before treatment,with statistically significant differences(P<0.05);LVEDD in the study group was less than that in the control group,PLT and TNF-α,IL-6 levels were lower than those in the control group,with statistically significant differences(P<0.05).During hospitalization and within 6 months after discharge,there was no significant difference in the total incidence of bleeding events between the two groups(P>0.05);During the treatment,the incidence of adverse reactions in the study group was signif-icantly lower than that in the control group(P<0.05).Conclusion AMI patients who receive indobufen combined with ticagrelor after PCI can experience improvements in cardiac function and coronary blood flow,effectively preventing platelet aggregation,alleviating postoperative inflammatory responses,and reducing ad-verse reactions,the combination offers higher safety and better efficacy compared with aspirin.